{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-006591","form_type":"8-K","ticker":"BMY","cik":"0000014272","company_name":"BRISTOL MYERS SQUIBB CO","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.433572+00:00","generated_at":"2026-06-27T04:43:32.514926+00:00","sec_items":["8.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"BMY reports 2021 Abraxane net sales of $1.18B, triggers $4.5M CVR payment","bullets":["Abraxane net sales for 2021: $1,181,043,283 as recorded in BMY financial statements.","Net Sales Payment to CVR holders: approximately $4,526,082, payable by March 7, 2022.","Per CVR payment: approx $0.104592, based on record date March 6, 2022.","Payment stems from CVRs assumed in 2019 Celgene acquisition under the CVR Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-006591","json":"https://secwatch.observer/filing/0001140361-22-006591.json","markdown":"https://secwatch.observer/filing/0001140361-22-006591.md","text":"https://secwatch.observer/filing/0001140361-22-006591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/14272/000114036122006591/0001140361-22-006591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14272/000114036122006591/brhc10034437_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:43:32.514926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}